Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

Company Overview - Neuronetics, Inc. is a global leader in neuroscience, focusing on mental health treatments, particularly through its NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions [5][6] - The company operates Greenbrook TMS Inc. treatment centers across the United States, providing NeuroStar Therapy for major depressive disorder and other mental health disorders [5] Public Offering Announcement - Neuronetics has commenced an underwritten public offering of its common stock, with an expectation to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares offered [1][2] - Canaccord Genuity LLC is acting as the sole bookrunner for this offering, which is subject to market conditions [2] Regulatory and Offering Details - A shelf registration statement for the common stock was filed with the SEC on November 9, 2022, and was declared effective on November 14, 2022 [3] - The offering will be conducted via a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3] Treatment Indications - NeuroStar Therapy is indicated for treating depressive episodes and reducing anxiety symptoms in adult patients with major depressive disorder who have not responded satisfactorily to previous antidepressant treatments [6] - The therapy is also FDA-cleared as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15 to 21 with major depressive disorder [6]